6.JPG)
Global Lipid Nanoparticles (LNPs) CDMO Market Size is valued at USD 205.4 Mn in 2024 and is predicted to reach USD 803.6 Mn by the year 2034 at a 14.8% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The advent of LNPs is aroused due to a high prevalence of infectious diseases, rising healthcare expenditures, and medical applications of nanoparticles.
- The increasing demand for medical applications of nanoparticles is expected to drive industry growth.
- North America dominated the market and accounted for a revenue share of global revenue in 2024.
- One of the significant concerns restraining industry growth is the lack of necessary infrastructure and high costs of outsourced services.
In recent years, a remarkable advancement in nanoscale drug delivery methods has been made. A novel nano-colloidal system for drug administration has emerged in the form of solid lipid nanoparticles (SLNs). Due to the lipid matrix's biocompatibility, lipid nanoparticles (LNPs) are frequently used in drug delivery. The most promising method for oral delivery is solid lipid nanoparticles (SLN), which have improved solubility, stability, permeability, and bioavailability while posing fewer side effects than standard dose formulations. Increasing clinical demand for small molecules is favoring the business of contract manufacturing service providers.
The most advanced non-viral therapeutically authorized mRNA delivery technologies are lipid nanoparticles (LNPs). The ability of an mRNA vaccine to deliver a therapeutic outcome is related to the capacity of LNPs to provide the nucleic acid intact into cells. For instance, in 2024, WACKER and CordenPharma signed a development collaboration in the field of lipid nanoparticle formulation. The two companies reported that they intend to jointly develop know-how and methods for manufacturing Lipid Nanoparticles (LNPs) to meet the growing market demand.
Major driving factors of the Lipid Nanoparticles (LNPs) CDMO market are the surging medical applications of nanoparticles, increasing investments by key players in lipid nanoparticles to develop promising drug therapies, rising cases of chronic diseases, an increasing aging population, and a growing number of health-conscious people. The rising chronic and infectious disease cases have increased pharmaceutical companies' product manufacturing burden. Hence, biopharma companies started to opt for contract manufacturing services to save time and handle lipid/nanoparticle production operations, which is expected to create business growth opportunities for the market over the forecast years. However, the high cost of outsourced services, lack of necessary infrastructure, need for specialized expertise for nanoparticle production, and complex manufacturing procedures may restrain the market growth during the estimated timeframe.
Competitive Landscape
Some major key players in the The Lipid Nanoparticles (LNPs) CDMO Market:
- Corden Pharma GmbH
- eTheRNA
- Curapath (Polypeptide Therapeutic Solutions (PTS))
- FUJIFILM Corporation
- ST Pharm Co Ltd
- Exelead (Merck KGaA)
- Avanti Polar Lipids, Inc. (Croda International Plc.)
- Emergent CDMO
- Esco Aster Pte Ltd
- Vernal Biosciences
- Recipharm AB
- Ardena Holding NV
- Curia Global, Inc.
- Helix Biotech
- Phosphorex Inc
- Polymun Scientific Immunbiologische Forschung GmbH
- Lonza Group AG
- Evonik
- Samsung Biologics
- Catalent, Inc
- Genevant Sciences
- Other Prominent Players
Market Segmentation
The Lipid Nanoparticles (LNPs) CDMO market is segmented based on product, scale of operation, end-users, and region. The product segment comprises mRNA, Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and others. By scale of operation, the market is classified into preclinical scale operations, clinical scale operations, and commercial-scale operations. The market is grouped into pharmaceutical companies, academic research institutes, and diagnostic laboratories. Pharmaceutical companies are projected to hold a significant market share over the forecast years owing to the high prevalence of chronic diseases and rising innovative drug developments. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
North America is estimated to witness rapid growth in the next few years due to the increasing awareness about the applications of nanoparticles, rising government investments in the R&D of nanoparticle products, and the high prevalence of chronic diseases.
Recent Developments
- In May 2024, ST Pharm initiated its global mRNA consignment development and manufacturing organization (CDMO) business by entering into a lipid supply agreement with Biotech in North America for a value of 17.7 billion won. Lipids play a crucial role in the production of mRNA-LNPs. LNPs is an abbreviation for lipid nanoparticles.
- In Mar 2024, eTheRNA Manufacturing announced the introduction of novel LNP formulation development and production services. The new LNP service allows for precise delivery and personalized distribution of substances by utilizing eTheRNA's unique lipid libraries and formulations. The newly established LNP service allows customers to optimize the delivery of their RNA products by leveraging the expertise of its specialized team.
The Lipid Nanoparticles (LNPs) CDMO Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 205.4 Million |
|
Revenue forecast in 2034 |
USD 803.6 Million |
|
Growth rate CAGR |
CAGR of 14.8% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Product, Scale of Operation, End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Corden Pharma GmbH, eTheRNA, Curapath (Polypeptide Therapeutic Solutions (PTS)), FUJIFILM Corporation, ST Pharm Co Ltd, Exelead (Merck KGaA), Avanti Polar Lipids, Inc. (Croda International Plc.), Emergent CDMO, Esco Aster Pte Ltd, Vernal Biosciences, Recipharm AB, Ardena Holding NV, Curia Global, Inc., Helix Biotech, Phosphorex Inc, Polymun Scientific Immunbiologische Forschung GmbH, Lonza Group AG, Evonik, Samsung Biologics, Catalent, Inc, Genevant Sciences, Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report; modifications to the regional and segment scope. Particular geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
